The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Current therapeutic management strategies in sickle cell disease
Abdullah Kutlar, MD, Augusta University, Augusta, GA, shares an overview of recent developments in the rapidly evolving sickle cell disease (SCD) therapeutic landscape. Three new agents have been approved in the last four years after each demonstrated beneficial disease modifying effects. Firstly, L-glutamine was approved in 2017, representing the first new treatment for adult patients in nearly 20 years. Following this, crizanlizumab, an anti-P-selectin monoclonal antibody, and voxelotor, a small molecule anti-sickling agent, were both approved in 2019. Acting via different mechanisms, both these novel agents are used in clinical practice to treat SCD. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
